CorMedix reported third quarter 2026 consolidated revenue of $54.5 million, beating expectations, with a net loss of $14.7 million and adjusted EBITDA of $3.1 million. The company announced an agreement to acquire substantially all assets of Heron Therapeutics, expected to close in Q1 2027, which will add four commercial products and significantly boost revenue. CorMedix maintains its full-year 2026 revenue guidance of $325-$345 million while narrowing adjusted EBITDA guidance to $130-$140 million. The company suspended 2027 DefenCath revenue guidance due to reimbursement changes but is optimistic about growth from the Heron acquisition and FDA review of its REZZAYO expanded indication expected in early 2027.
CorMedix Therapeutics reported third quarter 2026 consolidated revenue of $54.5 million and an adjusted EBITDA of $3.1 million. For readers following the Health sector, here is Pluang's market snapshot as of Nov 12, 2026 19:11 WIB: out of 150 priced US Health-sector stocks, 91 rose and 53 fell. Notable movers include SANA at USD 2.41 with a 5.24% increase and Pluang order activity of 6% Sell / 94% Buy, BNGO at USD 1.15 up 4.55% with 44% Sell / 56% Buy activity, and MMED at USD 17.50 down 4.11%, with a typical hold time of 19 days on Pluang.
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
ALS Canada, with renewed funding from TD Bank, is advancing its national strategy for ALS genetics to enhance access to genetic information, counselling, and care for Canadians affected by or at risk of ALS. This builds on the 2024 pilot of the first...
The Canadian ALS Society has renewed funding from TD Bank to expand its national genetics strategy for ALS, improving access to genetic information, counseling, and care for those affected or at risk. This initiative builds on a pilot project that cr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
